Coherus Oncology (CHRS) Net Margin Growth (1y) (2014 - 2026)
Powered by 
Analysis
Coherus Oncology (CHRS) Net Margin Growth (1y) (2014 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 802.00 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -16,220.00 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | -185.00 |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | -763.00 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 529.00 |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 4,168.00 |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 2,208.00 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -2,043.00 |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -753,036.00 |
| 10 | Coherus Oncology | 209.00 Mn | 103.70 Mn | 10.07 Mn | -304,811.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -304,811.00 |
| Mar 31, 2026 | 43,308.00 |
| Dec 31, 2025 | 36,029.00 |
| Sep 30, 2025 | -12,943.00 |
| Jun 30, 2025 | 302,941.00 |
| Mar 31, 2025 | -520,175.00 |
| Dec 31, 2024 | -56,855.00 |
| Sep 30, 2024 | -12,448.00 |
| Jun 30, 2024 | -5,248.00 |
| Mar 31, 2024 | 469,079.00 |
| Dec 31, 2023 | 4,278.00 |
| Sep 30, 2023 | 13,760.00 |
| Jun 30, 2023 | 1,036.00 |
| Mar 31, 2023 | -7,364.00 |
| Dec 31, 2022 | -6,747.00 |
| Sep 30, 2022 | -14,406.00 |
| Jun 30, 2022 | -4,926.00 |
| Mar 31, 2022 | 4,845.00 |
| Dec 31, 2021 | -7,110.00 |
| Sep 30, 2021 | -7,233.00 |